Genentech - About the company
Genentech is an acquired company based in San Francisco (United States), founded in 1976 by Youssef Idelcaid, Elisabeth Warren Pmp, Robert A Swanson and Herbert W Boyer. It operates as a R&D company focused on manufacturing drugs for multiple therapeutic areas. Genentech has raised $72.5M in funding, with last known valuation of $*****. The company has 1835 active competitors, including 94 funded and 204 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.
Company Details
R&D company focused on manufacturing drugs for multiple therapeutic areas. Its products include oncology, immunology, neurology, metabolism, infectious diseases, and ophthalmology drugs. It also provides clinical trial information services.
- Website
- www.gene.com/
- Social
- Registered Address
- South San Francisco, California
Key Metrics
Founded Year
1976
Location
San Francisco, United States
Stage
Acquired
Total Funding
$72.5M in 3 rounds
Latest Funding Round
Last Known Valuation
$***** as on Mar 12, 2009
Investors
Ranked
10th among 1835 active competitors
Employee Count
18,237 as on Aug 31, 2026
Investment & Acquisitions
Exit Details
Acquired by Roche (Mar 12, 2009)
Legal entities associated with Genentech
Genentech is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Genentech, Inc. CIN: 10176376 , United States, Active | Oct 14, 2021 | - | - | - |
Genentech, Inc. CIN: 942347624 , United States, Active | Dec 31, 1999 | - | 21619 (As on Dec 31, 2024) | - |
Genentech's acquisition details
Click here to take a look at Genentech's acquisition in detail
Sign up to download Genentech's company profile
Genentech's funding and investors
Genentech has raised a total funding of $72.5M over 3 rounds. Its latest funding round was a Grant (prize money) round on Jan 30, 2025 for $*****. 1 investor participated in its latest round. Genentech has 6 institutional investors.
Here is the list of recent funding rounds of Genentech:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 30, 2025 | 5970467 | Grant (prize money) | 8723336 | 1176271 | 7967701 | 9703716 |
Sep 22, 2023 | 1177090 | Grant (prize money) | 5858218 | 9224181 | 2637280 |
Access funding benchmarks and valuations. Sign up today!View details of Genentech's funding rounds and investors
Genentech's founders and board of directors
Founder? Claim ProfileThe founders of Genentech are Youssef Idelcaid, Elisabeth Warren Pmp, Robert A Swanson and Herbert W Boyer.
Here are the details of Genentech's key team members:
- Youssef Idelcaid: Founder & Co-Chair of the AI Summit Series of Genentech.
- Elisabeth Warren Pmp: Founder and Co-Chair, Genentech Women Professionals (GWP) of Genentech.
- Robert A Swanson: Former Co-Founder of Genentech.
- Herbert W Boyer: Former Co-Founder of Genentech.
- Alexander Hardy: ex-CEO of Genentech.
View details of Genentech's Founder profiles and Board Members
Genentech's employee count trend
Genentech has 18,237 employees as of Aug 26. Here is Genentech's employee count trend over the years:
Uncover Genentech's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Genentech's Competitors and alternates
Top competitors of Genentech include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Genentech, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 83/100 | |
2nd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 81/100 | |
3rd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 79/100 | |
4th |  AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 76/100 | |
5th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 75/100 | |
6th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 74/100 | |
7th |  Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 72/100 | |
8th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 71/100 | |
9th |  Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 70/100 | |
10th | Genentech 1976, San Francisco (United States), Acquired | R&D company focused on manufacturing drugs for multiple therapeutic areas | $72.5M | 68/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Genentech's competitors? Click here to see the top ones
Genentech's Investments and acquisitions
Genentech has made 14 investments in companies including Equify Health and Pieris Pharmaceuticals. Genentech has also acquired 5 companies including MyVisionTrack and Jecure Therapeutics.Here is the list of investments & acquisitions:
Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
May 31, 2023 | Investments | 2021 | Menlo Park (United States) | |
May 25, 2021 | Investments | 2001 | Boston (United States) | |
Feb 14, 2021 | Investments | 2021 | Menlo Park (United States) |
Want to know more about where corporates are investing? Sign up today!See all investments and acquisitions by Genentech
Reports related to Genentech
Here is the latest report on Genentech's sector:
News related to Genentech
Filter this listMedia has covered Genentech for a total of 49 events in the last 1 year, 25 of them have been about company updates and 6 about partnerships.
•
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier assetBioSpace•Oct 05, 2026•Alector, Genentech, NeOnc Technologies Holdings, Roche and 1 other
•
Genentech Expands Oregon Manufacturing Facility with $750M InvestmentContract Pharma•Sep 29, 2026•Genentech
•
Genentech and Earendil Labs Forge $1.5B+ Deal for AI-Driven Cancer TherapiesBioSpace•Sep 25, 2026•Genentech
•
•
•
DualityBio and Genentech Enter Global Collaboration for Next-Generation ADCsPR Newswire•Aug 28, 2026•Genentech, Duality Biologics
•
Hanmi Pharm inks $2.3B licensing deal with Genentech for obesity drug candidateThe Korea Times•Aug 24, 2026•Hanmi, Genentech, Roche, co.kr and 1 other
•
Genentech plans $750 million expansion to boost US drug manufacturing capacityGrupoglobo•Aug 20, 2026•Genentech
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Genentech
Explore our recently published companies
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company
